Ken Griffin Kezar Life Sciences, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,600 shares of KZR stock, worth $1,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,600

Previous 100,400 97.41%

Holding current value

$1,716

Previous $95,000 97.89%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.8 - $1.05 $115,388 - $151,446	144,235 Added 39.48%	509,564 $458,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $146,215 - $233,538	203,077 Added 125.16%	365,329 $347,000
Q3 2023 Nov 14, 2023	SELL	$1.08 - $2.54 $359,387 - $845,225	-332,766 Reduced 67.22%	162,252 $193,000
Q2 2023 Aug 14, 2023	SELL	$2.31 - $3.06 $1.09 Million - $1.44 Million	-471,000 Reduced 48.76%	495,018 $1.21 Million
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $2.93 Million - $6.85 Million	936,887 Added 3216.12%	966,018 $3.02 Million

Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $88,693 - $122,144	13,880 Added 91.01%	29,131 $205,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $358,327 - $482,105	-44,847 Reduced 74.62%	15,251 $131,000
Q2 2022 Aug 15, 2022	SELL	$4.58 - $17.13 $864,681 - $3.23 Million	-188,795 Reduced 75.85%	60,098 $497,000
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $1.78 Million - $2.66 Million	144,894 Added 139.32%	248,893 $4.14 Million
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $467,008 - $1.05 Million	62,770 Added 152.25%	103,999 $1.74 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $9.73 $57,249 - $114,852	11,804 Added 40.12%	41,229 $356,000
Q2 2021 Aug 16, 2021	SELL	$4.93 - $6.46 $10,249 - $13,430	-2,079 Reduced 6.6%	29,425 $159,000
Q1 2021 May 17, 2021	BUY	$5.24 - $6.99 $108,525 - $144,769	20,711 Added 191.89%	31,504 $188,000
Q4 2020 Feb 16, 2021	SELL	$4.77 - $6.58 $16,003 - $22,075	-3,355 Reduced 23.71%	10,793 $56,000
Q3 2020 Nov 16, 2020	SELL	$4.36 - $5.5 $14,632 - $18,458	-3,356 Reduced 19.17%	14,148 $68,000
Q2 2020 Aug 14, 2020	SELL	$3.6 - $7.75 $3.26 Million - $7.03 Million	-906,530 Reduced 98.11%	17,504 $91,000
Q1 2020 May 15, 2020	BUY	$2.77 - $5.75 $2.38 Million - $4.94 Million	859,760 Added 1337.65%	924,034 $4.03 Million
Q4 2019 Feb 14, 2020	SELL	$2.5 - $4.26 $5,480 - $9,337	-2,192 Reduced 3.3%	64,274 $258,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $7.58 $115,809 - $292,610	38,603 Added 138.55%	66,466 $218,000
Q2 2019 Aug 14, 2019	SELL	$7.09 - $21.9 $109,058 - $336,865	-15,382 Reduced 35.57%	27,863 $215,000
Q1 2019 May 15, 2019	BUY	$16.83 - $23.75 $727,813 - $1.03 Million	43,245 New	43,245 $0

Others Institutions Holding KZR

# of Institutions

Shares Held

45M

Call Options Held

2.6K

Put Options Held

600

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $45.1M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account